BioCentury
ARTICLE | Market Access

Merck rolling out molnupiravir at pandemic speed, scale

License to Medicines Patent Pool will make the drug available in 105 low- and middle-income countries

October 27, 2021 11:18 PM UTC

If molnupiravir withstands regulatory scrutiny, and if it turns out to be as safe and effective in treating COVID-19 as its developers believe, it will become available globally at a speed that rivals the spread of the virus it is intended to treat.

Merck & Co. Inc. (NYSE:MRK) and Ridgeback Biotherapeutics L.P. have put in place a comprehensive program to ensure that molnupiravir is manufactured globally, and to ensure rapid access to patients in low-, middle- and high-income countries...